Cosmetic Peptide

PTD-DBM

CXXC5-blocking peptide · PTD-DBM hair peptide · Dishevelled-binding motif peptide

Protein-transduction-domain + Dishevelled-binding motif peptide that competes with CXXC5 for Dvl, intended to lift a brake on Wnt/β-catenin in hair-follicle models. Foundational paper is mouse + dermal papilla cells (PMID 28595998). No completed human efficacy trial. Not minoxidil, not finasteride, not a prescription hair drug.

Not FDA-approved - research chemical

Quick answer

What it is: Protein-transduction-domain + Dishevelled-binding motif peptide that competes with CXXC5 for Dvl, intended to lift a brake on Wnt/β-catenin in hair-follicle models.

Typical research dose: Topical / microneedle research solutions (vendor); no established human dose

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Low·1 peer-reviewed citation

Typical research dose

Topical / microneedle research solutions (vendor); no established human dose

Frequency

Topical per vendor protocol

Half-life

Not established in humans

Common vials

5 mg / 10 mg

CAS

N/A

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Skin / cosmetic2.5/10
Lee 2017 mouse/dermal-papilla (PMID 28595998). No completed human AGA trial.

Compound card

Class: CXXC5/Dvl competitor + PTD (hair-follicle Wnt research peptide)
Formula: PTD + DBM (CXXC5 competitor)
Status: Not FDA-approved · research use

Dose it

5 mg + 2 mL BAC water → 2.5 mg/mL · 500 mcg ≈ 20 units (U-100)

Open in calculator

How it works

PTD-DBM is a cell-penetrating tag plus a Dishevelled-binding motif that competes with CXXC5 for Dvl, lifting a negative-feedback brake on Wnt/β-catenin in hair-follicle models. Lee et al. (J Invest Dermatol 2017, PMID 28595998) showed hair regrowth and wound-induced neogenesis in mice.

No completed human efficacy trial. Not minoxidil, not finasteride, not dutasteride. Microneedle + topical research use is vendor practice on top of a mouse paper.

Source: PMID: 28595998 (J Invest Dermatol 2017)

Mouse paper, not a hair drug

PMID 28595998 is real. A consumer vial is not that experiment. Do not delay standard AGA care.

Research Use Cases

✓Hair-catalog identity: Low

Dosing

Phase	Dose	Frequency	Notes
Human	None established	n/a	Calculator defaults are vial math for people who still reconstitute a powder. Not a protocol.

Administration

Route / form

Topical / microneedle in published mouse work and vendor SKUs

Timing

Not established in humans.

Empty stomach?

No - Food timing is not critical.

Timeline

Mouse study

Regrowth / WIHN in the 2017 paper - not a patient timeline.

Who it is for

Hair-catalog identity

Low

Listed because The Peptide Catalog and others sell it. Evidence is preclinical.

Reconstitution

Vial	Water	Concentration	Example dose
5 mg lyophilized	2 mL BAC	2.5 mg/mL	Topical/microneedle folklore. If lyophilized, confirm COA. No established human dose.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Wnt pathway tools are not gentle cosmetics by default. No human safety database for self-microneedling this peptide. Not a substitute for dermatologic AGA care.

Regulatory & Legal Status

FDA Status (US)

Research Only

Preclinical hair-follicle peptide (PMID 28595998). No human efficacy trial

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Human androgenetic alopecia is not wound-induced hair neogenesis in mice.
This site will not treat baldness from this page.

Verdict

PTD-DBM is a Wnt-brake competitor peptide from mouse hair models. Not minoxidil, not finasteride, not a prescription hair drug.

Interactions & Contraindications

Wnt pathway tools are not gentle cosmetics by default. No human safety database for self-microneedling this peptide. Not a substitute for dermatologic AGA care.

PTD-DBM vs. AHK-Cu

Canonical comparison: PTD-DBM vs AHK-Cu

Attribute	PTD-DBM	AHK-Cu
Job	CXXC5–Dvl competitor (Wnt)	Copper tripeptide (hair/cosmetic)
Evidence	Mouse + cell (PMID 28595998)	Cosmetic / in vitro copper-peptide
Human trials	None completed	None as a hair drug

Verdict: Both are hair-catalog peptides. PTD-DBM is a Wnt-pathway tool peptide. AHK-Cu is a copper tripeptide. Neither replaces minoxidil.

Frequently Asked Questions

Does PTD-DBM regrow hair in humans?▼

There is no completed peer-reviewed human efficacy trial. The flagship paper is mouse + cell (PMID 28595998).

Do I inject it?▼

The literature is topical on mouse skin. Vendor injectable SKUs are not that experiment.

References

Lee SH et al. “Targeting of CXXC5 by a competing peptide stimulates hair regrowth.” J Invest Dermatol (2017). PMID: 28595998

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library